Balchem Management
Management criteria checks 4/4
Balchem's CEO is Ted Harris, appointed in Apr 2015, has a tenure of 10.5 years. total yearly compensation is $6.87M, comprised of 16.8% salary and 83.2% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $8.94M. The average tenure of the management team and the board of directors is 3.7 years and 7.7 years respectively.
Key information
Ted Harris
Chief executive officer
US$6.9m
Total compensation
| CEO salary percentage | 16.81% |
| CEO tenure | 10.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.7yrs |
| Board average tenure | 7.7yrs |
Recent management updates
Recent updates
Balchem (NASDAQ:BCPC) Could Easily Take On More Debt
Sep 26
Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
Aug 26Balchem (NASDAQ:BCPC) Is Looking To Continue Growing Its Returns On Capital
Jul 21Balchem Corporation: The Next Earnings Release Should Guide Investors
Jul 14These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Safely
Jun 23When Should You Buy Balchem Corporation (NASDAQ:BCPC)?
May 26Estimating The Intrinsic Value Of Balchem Corporation (NASDAQ:BCPC)
May 12Do Balchem's (NASDAQ:BCPC) Earnings Warrant Your Attention?
Apr 17We Think Balchem (NASDAQ:BCPC) Can Manage Its Debt With Ease
Mar 21Balchem Corporation (NASDAQ:BCPC) Not Lagging Market On Growth Or Pricing
Mar 07A Look At The Intrinsic Value Of Balchem Corporation (NASDAQ:BCPC)
Jan 30Is Balchem (NASDAQ:BCPC) A Risky Investment?
Dec 19If EPS Growth Is Important To You, Balchem (NASDAQ:BCPC) Presents An Opportunity
Dec 06Balchem Corporation's (NASDAQ:BCPC) Earnings Haven't Escaped The Attention Of Investors
Nov 22Balchem's Q3 Shows Record Earnings And Valuation Pressure
Oct 28Here's What To Make Of Balchem's (NASDAQ:BCPC) Decelerating Rates Of Return
Oct 21Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
Oct 07Is Balchem (NASDAQ:BCPC) Using Too Much Debt?
Sep 09
Innovating In Nutrition And Health Sectors Drives Strong Financial Growth And Market Expansion
Launch of Optifolin+ in the nutrition segment and strong Human Nutrition & Health sales indicate potential for market share expansion and sustained revenue growth.Here's Why We Think Balchem (NASDAQ:BCPC) Might Deserve Your Attention Today
Aug 27Balchem Corporation's (NASDAQ:BCPC) Shares May Have Run Too Fast Too Soon
Aug 13Earnings Update: Here's Why Analysts Just Lifted Their Balchem Corporation (NASDAQ:BCPC) Price Target To US$184
Jul 31Return Trends At Balchem (NASDAQ:BCPC) Aren't Appealing
Jun 29Shareholders Will Most Likely Find Balchem Corporation's (NASDAQ:BCPC) CEO Compensation Acceptable
Jun 15Calculating The Intrinsic Value Of Balchem Corporation (NASDAQ:BCPC)
Jun 10Here's Why We Think Balchem (NASDAQ:BCPC) Is Well Worth Watching
May 26Balchem: A Tale Of Two Businesses
May 10Balchem Corporation's (NASDAQ:BCPC) Popularity With Investors Is Clear
Mar 21Is Balchem Corporation (NASDAQ:BCPC) Expensive For A Reason? A Look At Its Intrinsic Value
Mar 05Balchem: Potential Turnaround Is In The Price
Feb 21These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Reasonably Well
Feb 18Returns On Capital At Balchem (NASDAQ:BCPC) Have Stalled
Jan 03Balchem Corporation's (NASDAQ:BCPC) P/E Is On The Mark
Dec 19Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
Nov 20Balchem (NASDAQ:BCPC) Has A Pretty Healthy Balance Sheet
Oct 19The Returns At Balchem (NASDAQ:BCPC) Aren't Growing
Sep 09A Look At The Intrinsic Value Of Balchem Corporation (NASDAQ:BCPC)
Aug 22Is Balchem (NASDAQ:BCPC) A Risky Investment?
Jul 19Some Investors May Be Worried About Balchem's (NASDAQ:BCPC) Returns On Capital
May 28Calculating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
May 12Do Balchem's (NASDAQ:BCPC) Earnings Warrant Your Attention?
Apr 12We Think Balchem (NASDAQ:BCPC) Can Stay On Top Of Its Debt
Mar 14Balchem (NASDAQ:BCPC) Hasn't Managed To Accelerate Its Returns
Jan 11Here's Why We Think Balchem (NASDAQ:BCPC) Is Well Worth Watching
Dec 29Is Balchem (NASDAQ:BCPC) A Risky Investment?
Dec 13Balchem Corporation (NASDAQ:BCPC) Shares Could Be 26% Above Their Intrinsic Value Estimate
Nov 29Here's What To Make Of Balchem's (NASDAQ:BCPC) Decelerating Rates Of Return
Sep 20Balchem: Acquisitions And Cost Pressures Draw Attention
Sep 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$143m |
| Mar 31 2025 | n/a | n/a | US$137m |
| Dec 31 2024 | US$7m | US$1m | US$128m |
| Sep 30 2024 | n/a | n/a | US$122m |
| Jun 30 2024 | n/a | n/a | US$117m |
| Mar 31 2024 | n/a | n/a | US$115m |
| Dec 31 2023 | US$6m | US$1m | US$109m |
| Sep 30 2023 | n/a | n/a | US$103m |
| Jun 30 2023 | n/a | n/a | US$99m |
| Mar 31 2023 | n/a | n/a | US$99m |
| Dec 31 2022 | US$12m | US$1m | US$105m |
| Sep 30 2022 | n/a | n/a | US$109m |
| Jun 30 2022 | n/a | n/a | US$109m |
| Mar 31 2022 | n/a | n/a | US$102m |
| Dec 31 2021 | US$6m | US$1m | US$96m |
| Sep 30 2021 | n/a | n/a | US$93m |
| Jun 30 2021 | n/a | n/a | US$90m |
| Mar 31 2021 | n/a | n/a | US$88m |
| Dec 31 2020 | US$5m | US$1m | US$85m |
| Sep 30 2020 | n/a | n/a | US$83m |
| Jun 30 2020 | n/a | n/a | US$82m |
| Mar 31 2020 | n/a | n/a | US$81m |
| Dec 31 2019 | US$4m | US$915k | US$80m |
| Sep 30 2019 | n/a | n/a | US$80m |
| Jun 30 2019 | n/a | n/a | US$78m |
| Mar 31 2019 | n/a | n/a | US$78m |
| Dec 31 2018 | US$3m | US$800k | US$79m |
Compensation vs Market: Ted's total compensation ($USD6.87M) is about average for companies of similar size in the US market ($USD7.10M).
Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.
CEO
Ted Harris (60 yo)
Mr. Theodore Lee Harris, also known as Ted, has been the Chief Executive Officer and President at Balchem Corporation since April 28, 2015. He serves as an Independent Director of Pentair Plc since April 3...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 10.5yrs | US$6.87m | 0.19% $ 8.9m | |
| Executive VP | 6.7yrs | US$2.41m | 0.056% $ 2.6m | |
| Executive VP | 3.3yrs | US$1.56m | 0.0089% $ 418.4k | |
| Senior VP & Chief Supply Chain Officer | 4.8yrs | US$1.49m | 0.019% $ 915.6k | |
| Senior VP and GM of Human Nutrition & Health | 2.9yrs | US$1.88m | 0.0013% $ 59.4k | |
| VP & Chief Accounting Officer | 14.3yrs | US$960.42k | 0.020% $ 928.3k | |
| Senior Vice President of Corporate Development | 1.6yrs | US$1.01m | 0.039% $ 1.8m | |
| Senior VP & Chief Human Resources Officer | 3.7yrs | no data | 0.032% $ 1.5m | |
| Senior VP & GM of Specialty Products | 3.1yrs | no data | no data |
Experienced Management: BCPC's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 10.5yrs | US$6.87m | 0.19% $ 8.9m | |
| Independent Director | 7.7yrs | US$233.65k | 0.012% $ 577.7k | |
| Independent Director | 15.1yrs | US$220.65k | 0.024% $ 1.2m | |
| Lead Independent Director | 10.1yrs | US$248.65k | 0.016% $ 739.3k | |
| Independent Director | 2.1yrs | US$218.65k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$228.65k | 0.0016% $ 74.0k | |
| Independent Director | 2.1yrs | US$218.65k | 0% $ 0 |
Experienced Board: BCPC's board of directors are considered experienced (7.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 01:40 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Balchem Corporation is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Labick | CJS Securities, Inc. |
| Timothy Ramey | D.A. Davidson & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |